Skip to main content

Table 4 Clinical backgrounds between MACE and no-MACE group of CYP2C19*2 carriers

From: Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study

Clinical backgrounds

Total (n = 100)

MACE (n = 43)

No-MACE (n = 57)

P value

Male sex, n (%)

89 (89.0)

40 (93.0)

49 (86.0)

0.343

Age(years, mean ± SD)

58.0 ± 8.8

58.5 ± 8.6

57.6 ± 9.0

0.633

BMI (kg/m2, mean ± SD)

28.2 ± 3.9

28.9 ± 3.3

27.7 ± 4.2

0.122

Alcohol intake, n (%)

18 (18.0)

7 (16.3)

11 (19.3)

0.697

Smoking, n (%)

42 (42.0)

18 (41.9)

24 (42.1)

0.980

SBP (mmHg, mean ± SD)

133.3 ± 21.7

137.2 ± 26.6

131.5 ± 24.8

0.174

DBP (mmHg, mean ± SD)

79.5 ± 13.7

80.1 ± 12.7

79.0 ± 14.5

0.664

TG (mg/dL)

1.65 ± 0.78

1.67 ± 0.56

1.64 ± 0.73

0.887

LDL-C (mg/dL)

2.50 ± 0.90

2.43 ± 0.93

2.57 ± 0.88

0.426

HDL-C (mg/dL)

0.85 ± 0.20

0.85 ± 0.16

0.86 ± 0.23

0.684

TC (mg/dL)

3.98 ± 1.01

3.94 ± 0.98

4.0 ± 1.04

0.731

ALT (IU/L)

35.8 ± 18.7

30.5 ± 11.9

40.0 ± 17.7

0.205

AST (IU/L)

39.7 ± 16.0

35.2 ± 15.6

43.1 ± 16.4

0.375

Creatinine (μmol/ L)

72.1 ± 19.0

71.9 ± 25.2

72.3 ± 12.4

0.926

UA (μmol/ L)

321.1 ± 61.9

320.0 ± 56.0

322.0 ± 66.8

0.914

BG (mmol/ L)

6.52 ± 2.61

6.79 ± 2.83

6.32 ± 2.45

0.375

Clinical presentation, n (%)

 Unstable angina

49 (49.0)

20 (46.5)

29 (50.9)

0.665

 STEMI

32 (32.0)

13 (30.2)

19 (33.3)

0.742

 NSTEMI

24 (24.0)

13 (30.2)

11 (19.3)

0.205

Final treatment, n (%)

    

 PCI

82 (82.0)

38 (88.4)

44 (77.2)

0.15

 CABG

2 (2.0)

/

2 (3.5)

0.505

 Medical treatment only

17 (17.0)

5 (11.6)

12 (21.1)

0.214

Comorbidities, n%

 Hypertension

57 (57.0)

32 (66.7)

30 (48.4)

0.067

 Fatty liver

26 (26.0)

14 (32.6)

12 (21.1)

0.194

 Diabetes mellitus

37 (37.0)

20 (46.5)

17 (29.8)

0.087

 Dyslipidemia

83 (83.0)

37 (86.0)

46 (80.7)

0.481

History, n (%)

    

 Previous MI

23 (23.0)

9 (20.9)

14 (24.6)

0.669

 Previous PCI

13 (13.0)

5 (11.6)

8 (14.0)

0.723

 Previous CABG

1 (1.0)

/

1 (1.8)

1.0

Concomitant medication, n%

 Statin

96 (96.0)

41 (95.3)

55 (96.5)

1.0

 PPI

44 (44.0)

16 (37.2)

28 (49.1)

0.235

 CCB

26 (26.0)

12 (27.9)

14 (24.6)

0.706

 β-Blocker

82 (82.0)

37 (86.0)

45 (78.9)

0.36

 Diuretics

25 (25.0)

11 (25.6)

14 (24.6)

0.907

 ARB or ACEI

77 (77.0)

33 (76.7)

44 (77.2)

0.958

  1. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TC total cholesterol, ALT glutamic-pyruvic transaminase, AST glutamic-oxalacetic transaminase, UA uric acid, BG blood glucose, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, MACE major adverse cardiac events, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ARB angiotensin receptor blocker, ACEI angiotensin antagonist inhibitor, CCB calcium channel blocker, PPI proton pump inhibitor
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us